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Abstract. 
 
Stem cells are crucial for the formation and
maintenance of tissues and organs. The role of stem
cells in the pathogenesis of mosaic skin disorders re-
mains unclear. To study the molecular and cellular basis
of mosaicism, we established a mouse model for the
autosomal-dominant skin blistering disorder, epider-
molytic hyperkeratosis (MIM 113800), which is caused
by mutations in either keratin K1 or K10. This genetic
model allows activation of a somatic K10 mutation in
epidermal stem cells in a spatially and temporally con-
trolled manner using an inducible Cre recombinase.
Our results indicate that lack of selective pressure
against certain mutations in epidermal stem cells leads
to mosaic phenotypes. This ﬁnding has important impli-
cations for the development of new strategies for so-
matic gene therapy of dominant genodermatoses.
Key words: epidermolytic hyperkeratosis • keratins •
Cre recombinase • mosaic skin disease • gene therapy
 
Introduction
 
Mosaicism can be defined as a condition in which at least
two genetically distinct cell populations from the same dif-
ferentiation lineage exist within the same tissue. This con-
dition is usually caused by postzygotic mutations. The
genes that are mutated and the time point at which these
mutations occur determine the type of tissue that will be
affected and the extent of involvement. In skin, several
mosaic disorders have been described (Itin and Buechner,
1999) and are characterized by “islands” of abnormal skin
cells that presumably correspond to a clone of “mutated”
cells that arose from a single cell in which the mutation ini-
tially occurred (Happle, 1993). The mechanisms that lead
to clinical mosaicism are poorly understood. It remains un-
clear how certain genetic defects lead to a mosaic disease,
whereas others never become apparent in the same tissue.
A candidate disease to analyze the mechanisms that de-
termine how genetic mosaicism leads to a clinical pheno-
type is the keratin disorder epidermolytic hyperkeratosis
(EHK), which is characterized by a generalized and a mo-
saic form (Paller et al., 1994). Keratins are members of the
intermediate filament (IF) gene family and are mainly ex-
pressed in epithelial cells. They form a cytoskeletal scaf-
fold in keratinocytes of the epidermis to provide stability,
thus contributing to the mechanical integrity of the epider-
mis (Franke et al., 1981). Keratins are grouped into two
classes, the acidic type I (K9-K20) and the neutral-basic
type II (K1-K8) class (Moll et al., 1982). Keratins are obli-
gate heteropolymers that require equimolar amounts of
each type to assemble into IFs (Steinert and Liem, 1990).
The expression of keratin genes is highly regulated. The
pair of keratins that is expressed is usually specific for the
cell type and state of differentiation (Franke et al., 1981;
Roop, 1995). In the epidermis, IF assembly is a dynamic
process where newly synthesized filaments are integrated
into the existing network. In the basal cell compartment,
keratins K5 and K14 form the IF cytoskeleton and defects
in either keratin are associated with the autosomal-domi-
nant blistering disease, epidermolysis bullosa simplex
(EBS; Bonifas et al., 1991; Coulombe et al., 1991; Rothna-
gel and Roop, 1995). Keratins K1 and K10 are expressed
in keratinocytes that are committed to terminal differenti-
ation and point mutations in the corresponding genes have
been identified in EHK (Cheng et al., 1992; Chipev et al.,
1992; Rothnagel et al., 1992). The majority of mutations in
EHK are located in the same codon, affecting an evolu-
tionary highly conserved arginine residue. This site, codon
156 of the keratin 10 gene, has consequently been found to
be a “hot spot” for mutations due to CpG methylation and
deamination (Rothnagel et al., 1993).
 
The clinical course of EHK is severe and is characterized
by blistering and erythroderma (redness of the skin) at birth,
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and development of hyperkeratoses (thickening of the up-
permost layer of the epidermis) later in life, predominantly
over the flexural folds and in areas exposed to mechanical
stress (Digiovanna, 1999). Histologically, perinuclear vacu-
olar degeneration, lysis of the suprabasal keratinocytes and a
thickened stratum corneum are characteristic findings (Bale
et al., 1993). At the ultrastructural level, clumps of keratin fil-
aments are seen in a perinuclear distribution in suprabasal
keratinocytes; these clumps have been shown to contain ker-
atins K1 and K10 (Ishida-Yamamoto et al., 1992).
Whereas mosaic forms have been reported for EHK
where stripes of affected and unaffected skin alternate
(Paller et al., 1994), this has never been reported for EBS.
Why do these two keratin disorders behave so differently?
To investigate this question and to study the molecular
and cellular basis of mosaic diseases, we established a ge-
netic mouse model for EHK that allows focal activation of
a mutant K10 allele using a ligand-inducible Cre recombi-
nase (Kellendonk et al., 1996). Induction of the EHK le-
sions in a circumscribed area of the skin resulted in a phe-
notype characteristic of mosaic diseases, with patches of
affected and unaffected skin. Analysis of dissected kerati-
nocytes from lesional areas demonstrated activation of the
mutant allele in epidermal stem cells. We demonstrate
that mutant EHK stem cells and wild-type stem cells can
coexist in the basal layer of the epidermis, which may ex-
plain the persistent “islands” of phenotypic skin. Further-
more, we show that the severity of the clinical phenotype
in this mouse model correlates with the expression level of
the mutant allele. These findings have important implica-
tions for gene therapy approaches for dominant diseases
and these strategies can be tested in our model, as it mim-
ics the human disease at the genetic level. Finally, our re-
sults indicate that lack of selective pressure against certain
mutations in epidermal stem cells could explain how ge-
netic mosaicism results in clinical mosaicism.
 
Materials and Methods
 
Gene Targeting and Generation of Transgenic Mice
 
A BAC clone containing the full-length mouse keratin 10 gene was iso-
lated from a 129 SVJ genomic library (Incyte Genomics). Two overlap-
ping genomic fragments, a 4-kb EcoRI and a 6-kb BamHI fragment, were
fused at an EcoRI site in intron 2 to generate a 4.8-kb BglII-XhoI frag-
ment. The point mutation (CGC
 
®
 
TGC) was introduced by PCR-medi-
ated mutagenesis in the context of a 400-bp BstEII-NdeI fragment, which
was then reinserted into the targeting construct, thus replacing the wild-
type codon at position 154. A neo cassette (PGKneo) was inserted into a
unique NdeI site in intron 1 and this construct was introduced into the
KpnI and NotI sites of the pPNT vector which contains a herpes simplex
virus thymidine kinase gene under the control of the phosphoglycerate ki-
nase promotor (PGKtk; Tybulewicz et al., 1991). The procedures for em-
bryonic stem (ES) cell culture, electroporation, drug selection, and South-
ern blot analysis of targeted clones have been described previously
(Ramirez-Solis et al., 1993). In brief, the NotI-linearized targeting vector
(see Fig. 1 B) was electroporated into AB2.2 ES cells, which were main-
tained on SNL76/7 feeder plates (Bradley et al., 1992). ES clones were se-
lected in geneticin (G418) and FIAU (1(1-2-deoxy-2-fluoro-
 
b
 
-darabino-
furansyl)-5-iodouracil) and screened for homologous recombination by
Southern blot analysis, using probes derived from sequences not included
in the targeting construct (see Fig. 1 A) and an internal neomycin probe to
confirm a single integration event (data not shown). To excise the neomy-
cin resistance gene from the genome of targeted ES clones, ES cells were
electroporated with pOG231, a mammalian Cre expression vector. The
recombinant ES cells were injected into C57BL/6 blastocysts, followed by
transfer to pseudopregnant ICR females. Chimeric offspring were crossed
with C57BL/6 mice and agouti offspring carrying the targeted alleles (
 
1
 
/
mut
 
neo
 
; 
 
1
 
/mut
 
lox
 
) were identified by PCR analysis of genomic DNA ob-
 
tained from tail biopsies. Homozygous pups (mut
 
neo
 
/mut
 
neo
 
) were ob-
tained from heterozygous (
 
1
 
/mut
 
neo
 
) intercrosses. Bigenic (
 
1
 
/mut
 
neo
 
.
CrePR1) pups were obtained by mating heterozygous 
 
1
 
/mut
 
neo
 
 mice to
the previously described RU486-inducible Cre transgenic line (Berton et
al., 2000). RU486 (0.5 mg/ml in ethanol/DMSO) was topically applied
onto the skin of newborn bigenic mice once a day for 4–5 d until blisters
were visible.
 
Histology and Immunohistochemistry
 
Skin samples were processed as described and stained with hematoxylin
and eosin (Wojcik et al., 2000). Samples for double-label immunofluores-
cence were prepared as described previously (Bickenbach et al., 1996) and
sequentially incubated with primary antibodies: rabbit anti–mouse K10
and guinea pig anti–mouse K14 (Roop et al., 1984); then secondary anti-
bodies: swine anti–rabbit conjugate with FITC (Dako) and Texas red–
conjugated goat anti–guinea pig IgG (Vector Laboratories).
 
RNA Analysis
 
RNA was isolated from the epidermis of heterozygous pups with RNAzol
B (Tel-Test), as described previously (Wang et al., 1995). 2 
 
m
 
g of RNA
were reverse transcribed using Moloney murine leukemia virus (M-MLV)
reverse transcriptase and random primers, according to the manufac-
turer’s recommendation (Promega). A 280-bp fragment encompassing the
point mutation was amplified from the cDNA: 5
 
9
 
-biotin GGATTCG-
GAGGAGATGGTGG-3
 
9
 
 and 5
 
9
 
-biotin CAATCTGCAGCAGCAC-
GTTG-3
 
9
 
. Reverse transcription (RT)-PCR samples were digested with
AciI, analyzed by gel electrophoresis, followed by transfer to a positively
charged nylon membrane (Gene Screen Plus; NEN Life Science Prod-
ucts). As the point mutation destroys an AciI restriction site, the 280-bp
PCR product is cleaved into fragments of 210 and 70 bp in DNA from the
wild-type allele, but is resistant to digestion in DNA from the allele har-
boring the point mutation. The biotinylated DNA fragments were de-
tected using a nonisotopic chemiluminescent detection system (BrightStar
BioDetect; Ambion Inc.). Signals were visualized by autoradiography and
quantitated.
 
Laser Capture Microdissection
 
Skin biopsies from previously RU486-induced and -uninduced areas were
fixed in 10% formalin overnight, dehydrated through graded ethanol, and
embedded in paraffin. 5-
 
m
 
m sections were deparaffinized in xylenes,
rinsed in graded alcohols, and stained with Nuclear Fast Red (Vector Lab-
oratories). Sections were visualized using the PixCell I laser capture mi-
crodissection (LCM) system (Arcturus Engineering). A thermoplastic
polymer coating (ethylene vinyl acetate; CapSure) attached to a rigid sup-
port was placed in contact with the tissue section. The transfer film is acti-
vated by a near infrared laser pulse which melts the film onto the targeted
cells, thus forming a strong focal bond. 500–700 cells from the stratum spi-
nosum were captured per sample and DNA was extracted in a buffer con-
taining 1 mg/ml proteinase K, 0.5% Nonidet P-40, 0.25% Tween 20, 0.2
mM EDTA pH 8.0, and 10 mM Tris-HCl pH 8.0 and analyzed by PCR
with two primer pairs specific for the loxP (5
 
9
 
-GGGTTATTGAATAT-
GATCGG-3
 
9
 
 and 5
 
9
 
-AGGTAAGGCGCTTCAGACTC-3
 
9
 
) and neomy-
cin sequences (5
 
9
 
-ACAGCAAGGGGGAGGATTGG-3
 
9
 
 and 5
 
9
 
-TAC-
TATTCCTGCAGCCGACC-3
 
9
 
), respectively.
 
Results and Discussion
 
We have established a mouse model for the skin disease
EHK by introducing a K10 mutation, which is found in the
majority of human cases of EHK (Rothnagel et al., 1993),
into the mouse keratin 10 gene (Krieg et al., 1985). The
knock-in/replacement strategy was designed to replace the
wild-type amino acid arginine encoded by codon 154 (CGC)
with a sequence coding for cysteine (TGC) in ES cells by ho-
mologous recombination (Fig. 1). Heterozygous 
 
1
 
/mut
 
neo
 
and 
 
1
 
/mut
 
loxP
 
 mice were derived from ES clones that contain
a neomycin (neo) cassette or in which neo had been deleted
in vitro before injection into wild-type blastocysts, respec-
tively. These two lines express the mutant allele at different
levels, resulting in different phenotypes (see below).
For the inducible system, heterozygous 
 
1
 
/mut
 
neo
 
 mice
were used, as the neo cassette suppresses expression of the 
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mutant allele. Consequently, the animals develop a very
mild phenotype which is mainly restricted to skin exposed
to mechanical stress. Two mouse lines are required for the
inducible system, the first line harbors the target sequence
flanked by loxP sites (“floxed” neo cassette), and the sec-
ond line expresses an inducible form of Cre recombinase
(Kellendonk et al., 1996). The Cre transgene encodes a fu-
sion protein consisting of Cre recombinase and a trun-
cated form of a progesterone receptor (PR1), which is se-
questered in the cytoplasm until activated by topical
application of an inducer to the skin (e.g., RU486). Upon
ligand binding, the fusion protein translocates to the nu-
cleus, where Cre exerts its effect by excising any sequence
that is flanked by loxP sites in the same orientation. In re-
generating tissues like the epidermis, the excision event
will only be permanent if epidermal stem cells are tar-
geted. Therefore, the CrePR1 construct was placed under
the transcriptional control of an epithelial-specific promo-
tor that drives transgene expression in the basal layer of
the epidermis, where epidermal stem cells are located
(Berton et al., 2000). Bigenic mice were generated by
crossing these two lines (
 
1
 
/mut
 
neo
 
, CrePR1). Topical ap-
plication of RU486 to the ventral side of the trunk and ex-
tremities of newborn bigenic mice induced blistering at the
site of induction after three to five treatments (Fig. 2 A).
After the blisters ruptured, scaling developed around the
site of the previous blisters. With the onset of hair growth,
scaling diminished, leaving hyperkeratotic areas on the
paws (Fig. 2 B). These hyperkeratotic areas persisted and
developed into thick, brownish hyperkeratoses as seen in
older EHK patients (Digiovanna, 1999). Persistence of the
phenotype for 6 mo after the initial RU486 application
suggested that Cre-mediated excision of the neo cassette
had occurred in epidermal stem cells, as the epidermis is
renewed every 8–10 d in mice (Potten et al., 1987).
To investigate this hypothesis, LCM was performed to
isolate keratinocytes from persisting hyperkeratotic le-
sions (Fig. 2 C). As expected, the neo cassette was absent
in these cells (Fig. 2 D). This suggested that Cre-mediated
excision of the neo cassette and therefore activation of the
mutant allele had occurred in epidermal stem cells and
that these cells persisted and gave rise to daughter cells
Figure 1. Targeting of the mouse keratin 10
gene. (A) Genomic organization of the mouse
keratin 10 locus. Exon 1 contains codon 154 en-
coding arginine (R154). (B) The targeting vector
contains a C to T mutation encoding cysteine
(C154) which also destroys an AciI restriction
site. (C) Recombinant mutneo allele after homol-
ogous recombination in ES cells. (D) Recombi-
nant mutloxP allele after Cre-mediated excision of
PGKneo. 59 and 39: probes used for Southern
blot analysis. R, EcoRV; B, BglII; X, XhoI; S,
ScaI; A, ApaI; N, NotI; K, KpnI.
Figure 2. Inducible mouse model for EHK. (A) Bigenic 1/mutneo.
CrePR1 pup after four topical applications of RU486. Scaling
around the arm folds after rupture of the blister. No blisters devel-
oped in untreated bigenic 1/mutneo.CrePR1 pups or 1/mutneo or
CrePR1 pups treated with RU486 (data not shown). (B) Same
mouse 3 mo after induction. Note the thick brownish hyperkera-
toses on the paws. (C) Light micrograph of lesional skin from B.
Note the thickened stratum corneum, vacuolization, and translu-
cency in the suprabasal layer. Hematoxylin and eosin, bar 5 50 mm.
(D) PCR analysis of keratinocytes captured by LCM. PCR analysis
to detect the loxP site (top panel) and neo cassette (bottom panel).
1, suprabasal cells from previously treated area; 2, untreated area; 3,
wild-type control mouse; 4, 1/mutloxP mouse; and 5, 1/mutneo
mouse. M, DNA size marker. 
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that expressed the mutant allele in the suprabasal layers of
the epidermis. Cells from surrounding uninduced, clini-
cally normal areas contained the neo cassette. These re-
sults clearly demonstrate that keratinocytes containing the
neo cassette did not migrate into lesional areas.
Persistent “islands” of phenotypic skin were also ob-
 
served in chimeric mice derived from 
 
1
 
/mut
 
loxP
 
 ES cell
clones, where the neo cassette had been excised in vitro be-
fore injection into wild-type blastocysts. These mice exhib-
ited focal keratotic lesions on the paws at birth that devel-
oped into thick, brownish hyperkeratoses (Fig. 3, A and
B). The focal lesions in both the inducible model system
and the chimeras are equivalent to the linear, asymmetric
hyperkeratotic areas in humans in the mosaic form of
EHK, which is characterized by alternating stripes of af-
fected and unaffected skin that follow the lines of Blaschko
(Happle, 1987). It has been shown that the mosaic form is
caused by postzygotic K10 mutations that occur during em-
bryogenesis (Paller et al., 1994). Our analysis of the induc-
ible mouse model clearly suggests that in EHK, mutant
epidermal stem cells exist side by side with wild-type stem
cells. As the mutant K10 allele is not expressed in the basal
layer, there is no selection against mutant EHK epidermal
stem cells. In contrast, a selection process takes place
against defective epidermal stem cells in a mouse model
for EBS, when the mutant allele is focally activated in the
basal layer (Cao et al., 2001). This could explain why mo-
saic forms exist for EHK, but not for EBS.
An interesting aspect of the mouse models generated in
 
this study (
 
1
 
/mut
 
neo
 
, 
 
1
 
/mut
 
loxP
 
) is the correlation of a mild
phenotype with reduced expression of the mutant EHK al-
lele. Heterozygous mice that contain the point mutation
and the neo cassette (
 
1
 
/mut
 
neo
 
) exhibit a very mild scaling
phenotype due to suppressed expression levels of the mu-
tant allele. RNA analysis revealed that the mRNA from the
mutant allele was significantly reduced to 35–40% of the
levels of the wild-type allele (data not shown). To confirm
that mutant K10 mRNA was efficiently translated into
protein, we mated heterozygous 
 
1
 
/mut
 
neo
 
 mice to obtain
mice that were homozygous for the mutant allele (mut
 
neo
 
/
mut
 
neo
 
). These mice showed a very severe phenotype at
birth with extensive blistering and erosions, and died
shortly thereafter (Fig. 4 A). Skin biopsies showed a com-
plete disintegration of the stratum spinosum in lesional ar-
eas (Fig. 4 B). Immunofluorescence microscopy revealed
abundant K10 expression in the suprabasal layers of the
epidermis (Fig. 4 C). As the wild-type K10 allele is not
present in this mouse, all of the K10 protein detected is ex-
pressed from the mutant alleles. Therefore, the mutant K10
mRNA is translated into protein, but the presence of wild-
type K10 in heterozygous 
 
1
 
/mut
 
neo
 
 mice is sufficient to
overcome the effects of the reduced level of mutant K10.
Our EHK model has important implications for gene
therapy approaches. First, gene therapy approaches will
be different for EHK and EBS. Whereas repopulation of a
phenotypic area by corrected stem cells is predicted in the
case of EBS (Cao et al., 2001), successful approaches for
EHK will have to include a strategy that allows selection
of genetically corrected epidermal stem cells and ablation
of defective EHK stem cells. Recent studies suggest that it
may be possible to achieve selection of genetically modi-
fied epidermal stem cells by topical selection with cy-
tostatic and antimitotic compounds, such as colchicine
(Pfutzner et al., 1999).
Second, in contrast to the general assumption that gene
therapy approaches for dominant diseases must either cor-
 
Figure 3.
 
Chimeric mice de-
rived from 
 
1
 
/mut
 
loxP
 
 ES cells.
Thick hyperkeratoses on the
paws at 5 wk (A) and 3 mo of
age (B). (C) Normal paw.
Figure 4. Gross appearance and skin morphology of mutneo/
mutneo mice. (A) mutneo/mutneo pup shortly after birth with severe
blistering and erosions. (B) Histological analysis of a skin biopsy
from A shows a split in the suprabasal layer of the epidermis. He-
matoxylin and eosin, bar 5 50 mm. (C) Immunolabeling shows
abundant mutant K10 (yellow) throughout the disintegrating supra-
basal layer against the red K14 background stain. Bars 5 50 mm. 
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rect the mutant allele or completely inhibit its expression,
our data suggest that amelioration of the EHK phenotype
may be achieved by partial suppression of the mutant al-
lele or overexpression of the normal allele, thus altering
the ratio of wild-type to mutant protein. As our previous
transgenic studies have not revealed adverse effects from
an approximate twofold overexpression of a wild-type K1
allele (Bickenbach et al., 1996), it is intriguing to speculate
that overexpression of the wild-type protein two- to three-
fold might be sufficient to improve the phenotype in EHK
patients. This gene therapy approach may also be feasible
for other dominant diseases.
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